Therapeutic approaches in patients with inflammatory myopathies
- PMID: 12894385
- DOI: 10.1055/s-2003-41136
Therapeutic approaches in patients with inflammatory myopathies
Abstract
Among the group of inflammatory myopathies, dermatomyositis (DM) remains the most treatable subset responding, in the majority of the cases, to steroids, intravenous immunoglobulin (IVIg), or immunosuppressants. Inclusion-body myositis (IBM) remains the most difficult disease to treat; in uncontrolled studies immunosuppressants and steroids have not helped, and controlled trials with IVIg have been disappointing. Polymyositis (PM) is a very uncommon, although still overdiagnosed, disorder and its rarity poses difficulties in performing large-scale therapeutic studies; based on small series, however, PM seems to variably respond to immunotherapeutic interventions. The most consistent problem in the treatment of inflammatory myopathies remains the distinction of true PM from the difficult-to-treat cases of IBM, or from necrotizing myopathies and dystrophic processes where secondary endomysial inflammation may be prominent. The future in the management of PM, DM, and IBM seems promising because of the availability of new agents directed at T-cell activation molecules, cytokines, chemokines, and adhesion receptors. In IBM, the use of such immunomodulatory drugs may be combined with agents that block cytokine-enhancing amyloid or with agents that inhibit the formation and polymerization of amyloid fibrils.
Similar articles
-
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.Ann Rheum Dis. 2008 Dec;67(12):1670-7. doi: 10.1136/ard.2007.077974. Epub 2008 Feb 13. Ann Rheum Dis. 2008. PMID: 18272672 Clinical Trial.
-
Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.Ann Rheum Dis. 2007 Oct;66(10):1276-83. doi: 10.1136/ard.2006.058644. Epub 2007 Feb 2. Ann Rheum Dis. 2007. PMID: 17277004 Free PMC article.
-
Potential therapeutic _targets for idiopathic inflammatory myopathies.Drug News Perspect. 2006 Nov;19(9):549-57. doi: 10.1358/dnp.2006.19.9.1050424. Drug News Perspect. 2006. PMID: 17220960 Review.
-
High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials.Neurol Sci. 2003 Oct;24 Suppl 4:S256-9. doi: 10.1007/s10072-003-0090-6. Neurol Sci. 2003. PMID: 14598055 Review.
-
Update on idiopathic inflammatory myopathies.Autoimmunity. 2006 May;39(3):161-70. doi: 10.1080/08916930600622132. Autoimmunity. 2006. PMID: 16769649 Review.
Cited by
-
Treatment of inflammatory myopathies.Postgrad Med J. 2006 Jul;82(969):417-24. doi: 10.1136/pgmj.2005.038455. Postgrad Med J. 2006. PMID: 16822917 Free PMC article. Review.
-
Immunotherapy of myositis: issues, concerns and future prospects.Nat Rev Rheumatol. 2010 Mar;6(3):129-37. doi: 10.1038/nrrheum.2010.2. Epub 2010 Feb 2. Nat Rev Rheumatol. 2010. PMID: 20125096 Review.
-
Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.Clin Rev Allergy Immunol. 2005 Dec;29(3):255-69. doi: 10.1385/CRIAI:29:3:255. Clin Rev Allergy Immunol. 2005. PMID: 16391401 Clinical Trial.
-
Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.Ther Adv Neurol Disord. 2008 Nov;1(3):157-66. doi: 10.1177/1756285608097463. Ther Adv Neurol Disord. 2008. PMID: 21180574 Free PMC article.
-
Immunotherapy of inflammatory myopathies: practical approach and future prospects.Curr Treat Options Neurol. 2011 Jun;13(3):311-23. doi: 10.1007/s11940-011-0119-8. Curr Treat Options Neurol. 2011. PMID: 21365201
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
